KK-LC-1 TCR-T cells(Rutgers University)

N/A

Report date: 2022/08/15 14:11:03

Base Information

Drug NameKK-LC-1 TCR-T cells(Rutgers University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsAnti-Kita-kyushu lung cancer antigen 1
TargetsKita-kyushu lung cancer antigen 1
Therapy Area/IndicationsUterine Cervical NeoplasmsLung NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRutgers University
China Registration ClassN/A

Develop Information

Active CompaniesRutgers University
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsLung NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A